-
公开(公告)号：US20240360202A1
公开(公告)日：2024-10-31
申请号：US18760674
申请日：2024-07-01
申请人： Memorial Sloan-Kettering Cancer Center , Sloan-Kettering Institute for Cancer Research , Memorial Hospital for Cancer and Allied Diseases , Tri-Institutional Therapeutics Discovery Institute, Inc.
发明人： David A. Scheinberg , Tao Dao , Mary Ann Pohl , David Andrew , David Andrew
CPC分类号： C07K16/084 , A61K47/6839
摘要： The presently disclosed subject matter provides antibodies that mimic TCR recognition of HPV-derived epitopes presented by HLA class I molecules, antigen-recognizing receptors that target HPV-derived epitopes presented by HLA class I molecules, and methods of using such antibodies.
-
2.发明公开公开(公告)号：US20240239899A1
公开(公告)日：2024-07-18
申请号：US18561699
申请日：2022-05-19
申请人： Memorial Sloan-Kettering Cancer Center , Sloan-Kettering Institute for Cancer Research , Memorial Hospital for Cancer and Allied Diseases , Tri-Institutional Therapeutics Discovery Institute, Inc.
发明人： Tao DAO , David A. SCHEINBERG , Paul BALDERES , Mary Ann POHL
IPC分类号： C07K16/28 , A61K38/21 , A61K39/00 , A61P35/02 , C07K14/705
CPC分类号： C07K16/2833 , A61K38/217 , A61P35/02 , C07K14/70503 , A61K2039/505 , C07K2317/31 , C07K2317/32 , C07K2317/622 , C07K2317/732
摘要： The present technology relates generally to compositions that specifically recognize and bind to a serine-phosphorylated IRS2 (pIRS2) peptide RVA[pS]PTSGVK (SEQ ID NO: 19) complexed with a major histocompatibility antigen (e.g., HLA-A*02). The compositions of the present technology are useful in methods for treating pIRS2-associated diseases (e.g., cancers) in a subject in need thereof.
-
公开(公告)号：US20220213211A1
公开(公告)日：2022-07-07
申请号：US17693060
申请日：2022-03-11
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
IPC分类号： C07K16/28 , C07K14/705 , A61K35/17 , C07K14/725 , A61P35/00
摘要： The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target CD371 and cells comprising such CD371-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the CD371-targeted antigen-recognizing receptors for treatment.
-
公开(公告)号：US20240197879A1
公开(公告)日：2024-06-20
申请号：US18591191
申请日：2024-02-29
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
IPC分类号： A61K39/00 , A61P35/02 , C07K14/705 , C07K14/725 , C07K14/73 , C07K16/28 , C12N5/0783
CPC分类号： A61K39/464411 , A61K39/4611 , A61K39/4631 , A61P35/02 , C07K14/70503 , C07K14/7051 , C07K14/70514 , C07K14/70517 , C07K14/70521 , C07K14/70532 , C07K14/70578 , C07K16/2803 , C12N5/0636 , C07K2317/622 , C07K2319/02 , C07K2319/03
摘要： The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target CD33 and cells comprising such CD33-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the CD33-targeted antigen-recognizing receptors for treatment.
-
公开(公告)号：US20240131070A1
公开(公告)日：2024-04-25
申请号：US18535469
申请日：2023-12-11
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
发明人： Scott W. Lowe , Michel Sadelain , Corina Amor Vegas , Paul Balderes , Ivo C. Lorenz , Zeda Zhang
CPC分类号： A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/464429 , C07K16/2896 , A61K2239/21 , A61K2239/22 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622
摘要： The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target uPAR and cells comprising such uPAR-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the uPAR-targeted antigen-recognizing receptors for treatment.
-
6.发明公开公开(公告)号：US20240216557A1
公开(公告)日：2024-07-04
申请号：US18589649
申请日：2024-02-28
申请人： Memorial Sloan-Kettering Cancer Center , Sloan-Kettering Institute for Cancer Research , Memorial Hospital for Cancer and Allied Diseases , Tri-Institutional Therapeutics Discovery Institute, Inc.
发明人： John T. POIRIER , Charles Rudin , Jason Lewis , Abdul Khan , David Andrew , Xinlei Chen , Ivo C. Lorenz , Kathryn M. Tully , Salomon Tendler
IPC分类号： A61K51/10
CPC分类号： A61K51/1096 , A61K51/1018
摘要： The presently disclosed subject matter provides compositions and methods for in vivo diagnosis and treatment of diseases or disorders associated with DLL3. In particular, the presently disclosed subject matter provides novel anti-DLL3 antibodies-TCO conjugates, which can form a radioimmunoconjugate with a radioligand comprising a radioactive isotope.
-
公开(公告)号：US20240132480A1
公开(公告)日：2024-04-25
申请号：US18270621
申请日：2022-01-07
发明人： John Ginn , Shan SUN , Mayako Michino , Nigel Liverton , Rui Liang , Peter T. Meinke , David Huggins , Ruslana Bryk , Carl F. Nathan
IPC分类号： C07D403/12 , A61P31/06 , C07D209/08 , C07D209/34 , C07D209/42 , C07D231/56 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D513/04
CPC分类号： C07D403/12 , A61P31/06 , C07D209/08 , C07D209/34 , C07D209/42 , C07D231/56 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D513/04
摘要： Disclosed are compounds for inhibiting lipoamide dehydrogenase (Lpd), and methods of treating tuberculosis.
-
公开(公告)号：US20240262910A1
公开(公告)日：2024-08-08
申请号：US18592427
申请日：2024-02-29
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
CPC分类号： C07K16/2803 , A61K47/6849 , G01N33/58 , G01N33/6854 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/92 , G01N2333/70596
摘要： The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to CD33 and methods of using such antibodies or antigen-binding fragments thereof same.
-
公开(公告)号：US20240109973A1
公开(公告)日：2024-04-04
申请号：US18267992
申请日：2021-12-16
申请人： Memorial Sloan Kettering Cancer Center , Tri-Institutional Therapeutics Discovery Institute, Inc.
CPC分类号： C07K16/2878 , A61P35/00 , G01N33/68 , C07K2317/21 , C07K2317/24 , C07K2317/31 , G01N2333/70578
摘要： The present invention provides various CD40 binding molecules (including, but not limited to, antibodies), compositions comprising such CD40 binding molecules, and methods of using such CD40 binding molecules and compositions, for example for CD40-mediated activation of cells, such as antigen presenting cells.
-
公开(公告)号：US20240026009A1
公开(公告)日：2024-01-25
申请号：US18256384
申请日：2021-12-07
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
发明人： David SPRIGGS , Dharmarao THAPI , Ivo C. LORENZ , Thomas E. WHITE
CPC分类号： C07K16/2851 , A61K47/6849 , A61K49/0002 , C07K16/2809 , A61P35/00 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/622
摘要： Provided herein are compositions, methods, and uses involving antibodies that specifically bind the Galectin-3 (LGALS3) carbohydrate binding domain (CBD). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.016 秒)
